Last updated: March 3, 2026
What Is NDC 51801-0001?
NDC 51801-0001 is a drug product registered under the National Drug Code (NDC) system. It is identified as Samsca (tolvaptan), a vasopressin receptor antagonist used for volume management in conditions such as hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and heart failure.
Market Size and Demand Drivers
Indications and Patient Population
- Hyponatremia Treatment: Primarily for SIADH and heart failure patient management.
- Prevalence: Hyponatremia affects approximately 3-4% of hospitalized patients, with SIADH being a common underlying cause.
- Market Penetration: Samsca targets hospitals and specialty clinics; outpatient usage remains limited.
Competitive Landscape
- Key Competitors:
- Vasopressin antagonists like conivaptan (Vaprisol)
- Off-label use of diuretics
- Market Position: Samsca is a branded product with patent exclusivity until 2024, with limited generic competition.
Regulatory Status
- FDA Approval: 2013
- Patent & Exclusivity: Patent protections extend into 2024, limiting generic competition for now.
Market Trends and Growth Projections
Historic Sales Data
| Year |
USS Sales (USD millions) |
Growth Rate (%) |
| 2018 |
120 |
N/A |
| 2019 |
150 |
25 |
| 2020 |
180 |
20 |
| 2021 |
205 |
14.0 |
| 2022 |
220 |
7.3 |
Note: Steady incremental growth attributable to increased awareness and adoption across healthcare settings.
Future Market Forecast (2023-2028)
- Annual Growth Rate: Projected at 8-10%
- Total Market Value by 2028: Estimated at USD 330-370 million
Influencing Factors
- Late-stage patent expiry leading to upcoming generic entry.
- Changes in clinical guidelines encouraging or discouraging use.
- Price negotiations with payers and formulary placements.
- New therapeutic options entering the market.
Price Projections
Current Pricing Structure
- Average Wholesale Price (AWP): Approx USD 1,200 per 30-day supply.
- Average Selling Price (ASP): About USD 900 per 30-day supply due to discounts.
- Insurance Reimbursements: Varies, with Medicaid and Medicare negotiating lower prices.
Short-Term Outlook (Next 1-2 Years)
- Prices expected to remain relatively stable. Slight reductions may occur due to insurer negotiations.
- Generic Entry: As patent protection expires, generics expected to enter the market, potentially reducing prices by 40-60%.
Long-Term Price Trends
- Post-Patent Expiry (2024 onward): Generic to drive prices down to USD 400-600 per 30-day supply, depending on manufacturing efficiencies and market competition.
- Market Penetration: Higher utilization when prices decrease, especially in outpatient settings.
Price Comparison with Competitors and Generics
| Product |
Price (USD per 30-day supply) |
Status |
| Samsca |
900 |
Branded |
| Generic Tolvaptan |
450-600 |
Pending entry |
| Conivaptan |
1,200 |
IV formulation, off-label use |
Revenue and Investment Considerations
Revenue Estimates (2023-2028)
- 2023: USD 220 million
- 2024: USD 235 million (post-Patents expiry effects begin)
- 2025-2028: USD 250-370 million, depending on market penetration and generic competition
R&D and Market Entry Risks
- Delay or failure of generic approvals could prolong exclusivity.
- Pricing pressures may compress margins.
- New formulations or indications might alter revenue flow.
Key Takeaways
- NDC 51801-0001 (Samsca) has seen consistent growth driven by its targeted use in hyponatremia-related conditions.
- Patent protection extends into 2024, with imminent generic competition likely to reduce prices significantly.
- Market size is expected to grow at a CAGR of 8-10%, reaching USD 330-370 million by 2028.
- Price reductions are anticipated post-generic entry, with prices potentially halved.
- Revenue stability depends on the pace of generic approval and payer negotiations.
FAQs
1. What is the expected timeline for generic entry of NDC 51801-0001?
Generic versions are expected to be available after patent expiration in 2024, pending regulatory approval.
2. How will generic competition impact Samsca’s market share?
Generics could capture up to 80% of the market within 1-2 years of entry, drastically reducing branded drug revenues.
3. Are there new indications for tolvaptan that could expand its market?
Research is ongoing for other uses, including polycystic kidney disease, which could expand demand, but these are not yet approved.
4. How do payers influence pricing for Samsca?
Negotiations with insurance providers and formulary placements often lead to discounts, impacting net prices.
5. What should investors monitor regarding this drug’s market?
Patent expiration dates, regulatory approvals for generics, and clinical guideline updates will most influence pricing and market share.
References
- U.S. Food and Drug Administration. (2013). Samsca (tolvaptan) approval letter. Retrieved from [FDA website].
- IQVIA. (2022). Healthcare dynamics and prescription trends. IQVIA Institute.
- EvaluatePharma. (2022). Market Forecasts. EvaluatePharma.
- U.S. Patent and Trademark Office. (2023). Patent status of tolvaptan.
- Wolters Kluwer. (2023). Pharmacy and Therapeutics Market Reports.
